Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose Escalation Trial of Once Daily Oral Treatment BIBW 2992 Plus Gemcitabine or Docetaxel in Patients With Relapsed or Refractory Solid Tumors

Next Previous
Search
Trial Profile

A Phase I Dose Escalation Trial of Once Daily Oral Treatment BIBW 2992 Plus Gemcitabine or Docetaxel in Patients With Relapsed or Refractory Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary) ; Docetaxel; Gemcitabine
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 29 May 2018 Results (n=93) assessing the safety and efficacy of afatinib + gemicitabine or + docetaxel in patients with relapsed or refractory solid tumours, were published in the Investigational New Drugs.
    • 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top